Gene Therapy for Hemophilia A and B: Patient Selection and Follow-up, Requirements for a Cure

Introduction

The treatment of hemophilia A and B has improved considerably in recent years. The availability of hepatitis A and B vaccines, safer clotting factor concentrates (particularly recombinant factor VIII and recombinant factor IX concentrates), and synthetic agents, such as desmopressin,¹ has resulted in earlier, more aggressive treatment and prophylactic regimens aimed at preventing chronic, debilitating joint disease.^2-8There have been no new cases of human immunodeficiency virus (HIV) disease attributable to clotting factor in North America since 1987, and documented instances of hepatitis transmission by clotting factor concentrates have been rare in the 1990s. Concerns remain that certain nonenveloped viruses, such as human parvovirus B19 and hepatitis A virus, can still be transmitted by some plasma-derived clotting factor concentrates,⁹and questions linger as to whether the agents causing Creutzfeld-Jacob disease (CJD) and new variant CJD might also be transmitted. Overall, however, the products available to treat hemophilia today are safer than ever before.

An increasing number of persons with hemophilia are receiving exclusively recombinant (r) products, and manufacturers are now producing new, second-generation r-factor VIII products that are stabilized with sugars, rather than albumin, or are smaller, truncated molecules.¹⁰ Scientists are now designing specific changes into the factor VIII genes in an attempt to derive unique and improved forms of r-factor VIII.¹¹ The next logical areas of focus are to bring to fruition the promise of an “unlimited supply” of r-factor VIII and r-factor IX products, to meet the needs of persons with hemophilia, not only in developed countries, but throughout the world, and to be able to cure hemophilia through gene therapy.

As gene therapy trials begin in humans with hemophilia, the scientists involved, the United States Food and Drug Administration (FDA), and perhaps most importantly, members of the hemophilia community must decide which categories of affected individuals should be entered in these trials, particularly the earliest, Phase I trials. Who is most likely to benefit if gene therapy proves to be both effective and safe? Who should be the first patients to be enrolled in each new trial? Who is at greatest risk if something unexpected happens? What would be considered a good outcome? Clearly, some of these questions are more difficult to answer than others.

• References

• 1 Mannucci PM. Desmopressin: a nontransfusional hemostatic agent. Annu Rev Med 1990; 41: 55-64.
• 2 Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years’ experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232: 25-32.
• 3 Petrini P, Lindvall N, Egberg N, Blombäck M. Prophylaxis with factor concentrates in preventing hemophilic arthropathy. Am J Pediatr Hematol Oncol 1991; 13: 280-287.
• 4 van den Berg HM, Nieuwenhuis HK, Mauser-Bunschoten EP, Roosendaal G. Haemophilia prophylaxis in The Netherlands. Semin Hematol 1994; 31: 13-15.
• 5 Berntorp E. Methods of haemophilia care delivery: regular prophylaxis versus episodic treatment. Haemophilia 1995; 1 (Suppl. 01) 3-7.
• 6 Lofqvist T, Nilsson IM, Berntorp E, Pettersson H. Haemophilia prophylaxis in young patients: a long-term follow-up. J Intern Med 1997; 241: 395-400.
• 7 Berntorp E. Guidelines on treatment of haemophilia in Sweden. Haemophilia 1998; 4: 421-430.
• 8 Medical and Scientific Advisory Council. Recommendations concerning prophylaxis. Medical Advisory No. 193, Chapter Advisory No. 197. 1994. The National Hemophilia Foundation;
• 9 Lee CA. Transfusion-transmitted disease. Baillieres Clin Haematol 1996; 9: 369-394.
• 10 Lusher JM. Recombinant clotting factor concentrates. Baillieres Clin Haematol 1996; 9: 291-303.
• 11 Kaufman RJ, Pipe SW. Can we improve on nature? “Super molecules” of factor VIII. Haemophilia 1998; 4: 370-379.
• 12 Bird A, Isarangkura P, Almagro D, Gonzaga A, Srivastava A. Factor concentrates for haemophilia in the developing world. Haemophilia 1998; 4: 481-485.
• 13 Roberts HR, Hoffman M. Hemophilia and related conditions-inherited deficiencies of prothrombin (factor II), factor V and factors VII to XII. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ. eds. Williams Hematology. 5th Ed.. McGraw-Hill; New York, NY: 1995: 1413-1439.
• 14 Ahlberg Å. Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. Acta Orthop Scand 1965; 77 (Suppl. 01) 7-80.
• 15 Nilsson IM, Blombäck M, Ahlberg Å. Our experience in Sweden with prophylaxis on haemophilia. Bibl Haematol 1968; 34: 111-124.
• 16 Ljung RCR. Prophylactic treatment in Sweden: overtreatment or optimal model?. Haemophilia 1998; 4: 409-412.
• 17 Pettersson H, Gilbert M. Diagnostic Imaging in Hemophilia: Musculoskeletal and Other Hemorrhagic Complications. Springer-Verlag; Berlin: 1985: 56-65.
• 18 Pettersson H, Ahlberg Å, Nilsson IM. A radiologic classification of hemophilic arthropathy. Clin Orthop 1980; 149: 153-159.
• 19 Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73: 247-251.